Lupin Ltd gets USFDA approval for Cefdinir

New Delhi, May 9: Lupin Ltd today said it has received approval from the US Food and Drug Administrative to sell its anti-infective drug Cefdinir in Oral suspension form.

The company's Cefdinir capsules and suspensions are the AB-rated generic equivalent of Abbott Laboratories Omnicef which had the US sales of 787 million dollars for the 12-month period ended December 31, 2006.

Last year, Lupin received approval for the capsule form of the drug and a milder oral suspension, a company statement said.

Cefdinir is indicated for the treatment of patients with mild to moderate infections caused by susceptible bacteria.

UNI